摘要
目的探讨联合应用罗格列酮和二甲双胍治疗肥胖型2型糖尿病患者的临床效果,并初步分析其临床治疗安全性。方法选择63例肥胖型2型糖尿病患者,进行运动和饮食治疗的基础上,联合应用罗格列酮(4mg,1次/d)和二甲双胍(0.5g,3次/d)两种药物治疗14周,比较治疗前后所有患者的空腹血糖(FBS)、餐后血糖(PBS)、糖化血红蛋白(HbA1c)、空腹胰岛素(FINS)、餐后胰岛素(PINS)等血糖相关指标,超敏C-反应蛋白(hs-CRP)等炎性反应相关指标,血脂[包括总胆固醇(TC)、三酰甘油(TG)、高密度脂蛋白(HDL)、低密度脂蛋白(LDL)]、体重指数(BMI)、血压[收缩压(SBP)、舒张压(DBP)]、腰围等肥胖与血压相关指标。密切监测患者生理功能变化以及任何不良反应发生情况和处理结果。结果治疗14周后,FBS、PBS、PINS、hs-CRP、HbA1c、TG、LDL、BMI、腰围等指标较治疗前明显下降,HDL明显上升,且差异有统计学意义(P<0.05),TC、FINS、SBP、DBP、BMI等指标较治疗前有所下降,但差异无统计学意义(P>0.05)。2例味觉异常,3例出现消化道反应,5例转氨酶轻度升高,经对症处理后上述症状消失。所有患者未出现肾功能异常或其他生理功能异常情况。结论联合应用罗格列酮和二甲双胍治疗肥胖型2型糖尿病患者具有明显的临床治疗效果,能够调节血糖和胰岛素代谢水平,同时对于血压、血脂和炎症因子也有作用,且不良反应发生少。
Objective To discuss the clinical features of multiple myleoma.Methods 63 obese type 2 diabetes patients were selected as research subjects.Including exercise and diet treatments,all patients were treated combing rosiglitazone（4mg,qd）with dimethyldiguanide（0.5g,tid）14 weeks,and then indexes like FBS、PBS 、HbA1c、 FINS、 PINS、 hs-CRP、 TC、 TG、 HDL、 LDL、 BMI、 SBP and DBP before treatment were compared after treatment.During the research,physiological functions and any untoward effects were monitored and handled.Results 14 weeks later,indexes like FBS、PBS、PINS、hs-CRP、HbA1c、TG、LDL、BMI declined significantly,HDL ascended,statistical significance was found（P〈0.05）.TC、FINS、SBP、DBP、BMI decline,but statistical significance was not found（P〉0.05）.Two of the patients shew flu-like symptom,3 had symptoms of digestive tract.All symptoms disappeared after treatment.None had abnormal physiological functions.Conclusion Combination rosiglitazone with dimethyldiguanide in obese type 2 diabetes patients show obvious clinical effects,and regulate blood sugar and insulin metabolism.The treatment will be helpful in blood pressure、blood-fat and inflammation response with less untoward effects.
出处
《四川医学》
CAS
2010年第3期318-320,共3页
Sichuan Medical Journal
关键词
罗格列酮
二甲双胍
肥胖
2型糖尿病
血糖
血脂
炎性因子
rosiglitazone
dimethyldiguanide
obesity
type 2 diabetes
blood sugar
blood-fat
inflammation factors
